GlassScriptPhysician profile
Jean-Jacques Rajter
NPI 1720043607
$7,636.95
in general payments reported to CMS, 2019-2025
27 companies · $2,326 in 2025
The $2,326 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $831 · 2020: $93.51 · 2021: $7.50 · 2022: $42.70 · 2023: $3,777 · 2024: $559 · 2025: $2,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,620 · Food and Beverage: $1,760 · Travel and Lodging: $1,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,620.10 |
| Food and Beverage | $1,760.04 |
| Travel and Lodging | $1,281.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,489.13 | 2023 | Ion, Da Vinci Surgical System |
| Inspire Medical Systems, INC. | $1,498.52 | 2023-2025 | Inspire |
| Glaxosmithkline, LLC. | $379.30 | 2019-2025 | Nucala, Trelegy Ellipta |
| Insmed, INC. | $340.04 | 2019-2025 | Arikayce, Brinsupri |
| Jazz Pharmaceuticals INC. | $271.94 | 2025 | |
| Mallinckrodt Hospital Products INC. | $256.77 | 2023-2024 | Acthar |
| Actelion Pharmaceuticals US, INC. | $217.74 | 2019-2025 | Uptravi, Opsumit |
| Mallinckrodt Enterprises LLC | $165.09 | 2019 | |
| Grifols USA, LLC | $156.65 | 2019-2025 | Prolastin-C Liquid |
| Ani Pharmaceuticals, INC. | $135.04 | 2024-2025 | Purified Cortrophin Gel |
| Avadel Cns Pharmaceuticals, LLC | $86.68 | 2024-2025 | Lumryz |
| United Therapeutics Corporation | $73.34 | 2021-2025 | Tyvaso |
| Astrazeneca Pharmaceuticals LP | $71.43 | 2019-2025 | Breztri |
| Axsome Therapeutics, INC. | $67.00 | 2025 | Sunosi |
| Sunovion Pharmaceuticals INC. | $58.16 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $50.27 | 2025 | Yupelri |
| Mylan Specialty L.P. | $46.40 | 2020-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.93 | 2019 | |
| Medtronic, INC. | $43.97 | 2024 | Illumisite |
| Gilead Sciences, INC. | $37.39 | 2019 | |
| Electromed, INC. | $35.60 | 2019 | |
| Pfizer INC. | $31.61 | 2019-2020 | |
| Shire North American Group INC | $20.07 | 2019 | |
| Philips North America LLC | $15.52 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $14.83 | 2025 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $14.82 | 2019 | |
| Harmony Biosciences LLC | $14.71 | 2023 | Wakix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean-Jacques Rajter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.